Clinical Trials Logo
  1. Home
  2. Latent Tuberculosis Infection
  3. NCT05746611

Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein

Latent Tuberculosis Infection Clinical Trial

Official title:
To Conduct a Phase IV Clinical Trial of Recombinant Mycobacterium Tuberculosis Fusion Protein in Community Population Aged 6 Months and Above.

Clinical Trial Summary

Cohort 1 was a randomized, double-blind, controlled clinical trial with a planned enrollment of 500 patients. Cohort 2 is a non-randomized, open-label clinical trial with a planned enrollment of approximately 60000 patients. Cohort I was injected with EC and TB-PPD in both arms, and cohort II was injected with EC only

Clinical Trial Description

Assessment of effectiveness: In cohort 1, the injection site reaction was examined at 0min, 24h, 48h and 72h after skin test, and the transverse and longitudinal diameters of the erythema and induration were measured and recorded in millimeters (mm), the larger the erythema or induration. Any blisters, necrosis, lymphangitis should be faithfully recorded. In cohort 2, the injection site reaction was examined at 0min and 48-72 h after skin test, and the transverse and longitudinal diameters of the erythema and induration were measured and recorded in millimeters (mm), the larger the erythema or induration. Any blisters, necrosis, lymphangitis should be faithfully recorded. Safety assessments: The safety assessment included all expected and unexpected medical events that occurred during the observation period of the clinical trial (within 72 hours after the skin test) and were related or unrelated to the injection of the investigational drug. These included specific reactions such as redness, induration, blister, necrosis, and lymphangitis at the injection site (palmar forearm). Common and occasional adverse reactions include: Local adverse reactions: injection site pruritus, injection site pain, injection site rash; Systemic adverse reactions included fever, headache, nausea, fatigue, myalgia, diarrhea, vomiting, paresthesia. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05746611
Study type Interventional
Source Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Contact Yi Mo, Master
Phone 13788686968
Email moyi0415@qq.com
Status Recruiting
Phase Phase 4
Start date April 17, 2023
Completion date June 30, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT04094012 - Risk of SDRs Under 3HP and 1HP Regimen for LTBI Phase 3
Completed NCT01582711 - Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT Phase 3
Recruiting NCT06033807 - Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients
Completed NCT01622140 - Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis
Completed NCT00557765 - Use of a Gamma-IFN Assay in Contact Tracing for Tuberculosis in a Low-Incidence, High Immigration Area N/A
Completed NCT00463086 - Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons N/A
Active, not recruiting NCT01398618 - Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI) Phase 3
Recruiting NCT00905970 - Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection N/A
Recruiting NCT00449345 - Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis N/A
Completed NCT02641106 - VDOT for Monitoring Adherence to LTBI Treatment N/A
Completed NCT00804713 - Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits N/A
Completed NCT01136161 - Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection Phase 2
Recruiting NCT03312647 - Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection N/A
Completed NCT02810678 - Enhancing the Public Health Impact of Latent Tuberculosis (TB) Infection Diagnosis and Treatment N/A
Completed NCT01223534 - QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study. Phase 4
Withdrawn NCT00558480 - Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis N/A
Recruiting NCT00692809 - Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infection N/A
Completed NCT03702049 - Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV N/A
Terminated NCT01761201 - "Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients". Phase 3
Completed NCT01608685 - Interferon Gamma Release Assays (IGRA) Testing Versus Tuberculin Skin Test in Renal Transplant Recipients N/A